Hims & Hers Health Inc. (NYSE:HIMS) finished Wednesday with an addition of $0.4 to close at $8.35, an upside of 5.03 percent. An average of 1,952,180 shares of common stock have been traded in the last five days. There was a gain of $0.99 in the past week. The last 20 days have seen an average of 2,102,125 shares traded, while the 50-day average volume stands at 2,664,266.
HIMS stock has decreased by -3.58% in the last month. The company shares reached their 1-month lowest point of $7.18 on 10/06/21. With the stock rallying to its 52-week high on 02/08/21, shares of the company touched a low of $6.71 and a high of $25.40 in 52 weeks. In spite of this, the price is down -67.13% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
118 days have passed since Hims & Hers Health Inc. (HIMS) last reported insider trading activity. Lee Spencer, who is Chief Financial Officer, most recently acquired $13,690 shares at $12.07 per share on Jun 18. In this transaction, the insider spent $165,238. Chief Executive Officer, Dudum Andrew, disposed of 22,142 shares at a price of $12.07 on Jun 18. The insider now owns more than $267,254 worth of shares. Prior to that, Chief Operating Officer Baird Melissa went on to Sale 9,571 shares at $12.07 each on Jun 18. An amount of $115,522 was transacted.
Hims & Hers Health Inc. (HIMS) has a trailing price-to-earnings (P/E) ratio of 18.75 for the broader industry and 24.47 for the sector. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 14.52, the price-to-book (PB) ratio at 5.46.
The quick ratio of Hims & Hers Health Inc. for the three months ended June 29 was 12.10, and the current ratio was 12.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Hims & Hers Health Inc.’s return on assets was -23.50%. For the broader industry, ROE averaged 12.06 over the past year.
For the three-month period that ended June 29, Hims & Hers Health Inc. had $210.18 million in cash. The analyst consensus anticipated Hims & Hers Health Inc.’s latest quarter earnings to come in at -$0.08 per share, but it turned out to be -$0.03, a 62.50% surprise. For the quarter, EBITDA amounted to -$16.9 million. At the end of the quarter ending June 29, Hims & Hers Health Inc.’s stock balance sheet showed total liabilities of 54.65 million. Shareholders own equity worth $203.23 million.
From a technical analysis perspective, let’s take a brief look at Hims & Hers Health Inc. (HIMS) price momentum. RSI 9-day as of the close on 13 October was 66.79%, suggesting the stock is Neutral, with historical volatility in this time frame at 42.11%.
As of today, HIMS’s price is $7.72 +13.45% or $0.99 from its 5-day moving average. HIMS is currently trading -3.58% lower than its 20-day SMA and -34.82% lower than its 100-day SMA. However, the stock’s current price level is +2.20% above the SMA50 and -44.07% below the SMA200.
The stochastic %K and %D were 57.19% and 36.19%, respectively, and the average true range (ATR) was 0.46. With the 14-day stochastic at 88.64% and the average true range at 0.48, the RSI (14) stands at 58.27%. The stock has reached 0.39 on the 9-day MACD Oscillator while the 14-day reading was at 0.27.
BofA Securities launched coverage on Hims & Hers Health Inc. (NYSE: HIMS) in its analyst report released on July 06, 2021. The firm assigned the stock a a Neutral rating.The consensus rating for Hims & Hers Health Inc. (HIMS) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell HIMS, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is HIMS’s price target for the next 12 months?
Analysts predict a range of price targets between $10.00 and $14.00, with a median target of $11.50. Taking a look at these predictions, the average price target given by analysts for Hims & Hers Health Inc. (HIMS) stock is $11.75.